Company intelligence / Profile preview

GeneArt

Regensburg, Bavaria, Germany

Ownership: Private
Employees: ~300
Development stage: Other

Overview

GeneArt, now a Thermo Fisher Scientific business, is a leading provider of synthetic gene services and proprietary DNA engineering platforms widely used in research and early drug/vaccine development, supporting numerous projects from preclinical studies through the manufacturing of DNA and protein reagents for clinical and commercial applications.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Gene therapyDNA synthesismRNA-based drugsMonoclonal antibodyVaccineProteinCell therapyAntibody
Industry: Non-Drug Biotech

Partnerships

Numerous partnerships/clients in biotech, pharma, and academia (e.g., Novozymes, EU FP projects, pharma companies for vaccine development)

Beyond the preview

Go deeper on GeneArt.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneArt.

Explore the full profile